Airlines Were on Time in 2020, but Passenger Flights Operated Halved Compared to 2019, Reveals Cirium
4.1.2021 20:15:00 EET | Business Wire | Press release
Over 180 of the major global airlines were on time in 2020, according to a new report by Cirium, the global aviation data company. The Cirium Airline Insights Review 2020 reveals that only 30 major airlines achieved this standard pre-pandemic. But over 60%—or 180 of 300 airlines globally—achieved a 90% or higher on-time arrival percentage since February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210104005632/en/
Cirium’s new report The Cirium Airline Insights Review 2020 reveals the world’s top 10 busiest airports of 2020. (Graphic: Business Wire)
On-time performance of the top 300 global airlines significantly improved as COVID-19 reduced the number of flights in the air. In 2020, airlines only flew half of the flights flown the previous year.
“The pandemic caused a significant reduction in flight volume with airlines operating 49% fewer flights in 2020. The factors that normally cause flight delays didn’t exist, such as congestion at the airport. Overall global passenger traffic was down in 2020 by 67% from the previous year,” said Jeremy Bowen, CEO of Cirium.
Cirium’s top 10 league table for flights operated by country shows that the majority of flights were operated in the US, despite a 42% year-over-year drop in the market. China maintained its position, with only 24% of that market’s flights down versus 2019.
Japan overtook India, moving up to 3rd place as India’s flights were down 50% versus 2019. The UK was hit heavily with 67% of flights down compared to last year, moving it to 8th place from 5th. Russia moved from 10th place in 2019 to 5th in 2020 and Indonesia moved into the top 10.
|
Top 10 countries by passenger flights flown 2020 |
||||
|
Rank |
Country |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
United States |
5.1M |
#1 |
-42% |
|
2 |
China |
3.4M |
#2 |
-24% |
|
3 |
Japan |
638K |
#4 |
-43% |
|
4 |
India |
592K |
#3 |
-50% |
|
5 |
Russia |
486K |
#10 |
-34% |
|
6 |
Brazil |
382K |
#9 |
-53% |
|
7 |
Spain |
352K |
#7 |
-61% |
|
8 |
United Kingdom |
340K |
#5 |
-67% |
|
9 |
Indonesia |
333K |
#12 |
-53% |
|
10 |
Mexico |
332K |
#15 |
-44% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
||||
Asia-Pacific carriers recovered much quicker in 2020 than their global peers and rose in the rankings in flights operated. Out of the top 10 global airlines, China Southern Airlines’ passenger flights only dropped 28% versus 2019. United Airlines was the most impacted of the top 10, with a 54% drop in flights flown versus 2019.
No European carriers feature in the 2020 list. Ryanair moved to 13th place (from 6th) as the airline’s flights flown were down 72% versus the year before. Lufthansa was 11th in 2019 but missed out on the 2020 top 10, finishing at 29th place as flights flown dropped by 69% in 2020.
|
Top 10 airlines by passenger flights flown 2020 |
|||||
|
Rank |
Airline code |
Airline |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
WN |
Southwest Airlines |
896K |
#1 |
-34% |
|
2 |
AA |
American Airlines |
622K |
#3 |
-44% |
|
3 |
DL |
Delta Air Lines |
619K |
#2 |
-46% |
|
4 |
OO |
SkyWest Airlines |
597K |
#4 |
-30% |
|
5 |
CZ |
China Southern Airlines |
521K |
#7 |
-28% |
|
6 |
UA |
United Airlines |
372K |
#5 |
-54% |
|
7 |
MU |
China Eastern Airlines |
321K |
#9 |
-33% |
|
8 |
CA |
Air China |
312K |
#10 |
-30% |
|
9 |
6E |
IndiGo |
281K |
#8 |
-45% |
|
10 |
YX |
Republic Airways |
217K |
#15 |
-37% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
“Domestic travel has recovered faster and airlines with a dominant domestic market come back quicker,” Bowen said. “That is especially the case in Asia-Pacific where recovery is more positive. The US and Europe have experienced setbacks with government-enforced restrictions and additional waves of COVID-19 affecting travel.”
Travel restrictions and the shift to more leisure travel versus business travel changed the top 10 league table for flights flown by airport extensively.
Chicago O’Hare is usually the busiest airport globally for passenger flights, however the pandemic caused a 46% reduction in flights for the airport in 2020. Three Chinese airports—Guangzhou Baiyun, Chengdu Shuangliu, and Shenzhen Bao’an—moved into the global top 10 busiest airports by arriving passenger flights.
|
Top 10 airports by passenger flights flown 2020 |
|||||
|
Rank |
Airport code |
Airport |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
ATL |
Atlanta US |
260K |
#2 |
-40% |
|
2 |
DFW |
Dallas US |
235K |
#3 |
-30% |
|
3 |
ORD |
Chicago US |
234K |
#1 |
-46% |
|
4 |
DEN |
Denver US |
202K |
#5 |
-32% |
|
5 |
CLT |
Charlotte US |
182K |
#7 |
-32% |
|
6 |
CAN |
Guangzhou CN |
165K |
#13 |
-28% |
|
7 |
LAX |
Los Angeles US |
156K |
#4 |
-50% |
|
8 |
CTU |
Chengdu CN |
148K |
#37 |
-16% |
|
9 |
SZX |
Shenzhen CN |
139K |
#42 |
-16% |
|
10 |
SEA |
Seattle US |
137K |
#18 |
-36% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
In 2019, London Heathrow was the 9th busiest airport for flights flown. In 2020, it ranked 31st and flights operating there were down 61% versus 2019. Amsterdam Airport Schiphol was the busiest airport in Europe. Flight operations there dropped 57% in 2020 and as a result the airport sits at 27th globally.
The Cirium Airline Insights Review 2020 provides additional insights on 2020 air travel industry and includes The On-Time Performance Review 2020 by Cirium.
To read the full Cirium Airline Insights Review 2020 – click here.
Ends
Note to editors:
Data for the passenger flights flown is based on set criteria, which includes passenger flights only (including combination flights – passenger and cargo) that are scheduled and aircraft market classes of narrowbody, widebody, and regional jets. It excludes other types, such as cargo and business jet flights, as well as unscheduled flights.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005632/en/
Contact information
For media enquiries, please contact,
In the UK: Paul Charles / Michael Johnson / Balint Brunner at The PC Agency via cirium@pc.agency or +44 207 768 0001
In the Americas: Mike Arnot, at Juliett Alpha via cirium@juliettalpha.com
In Asia-Pacific: Tracy Cheung, at Cirium via tracy.cheung@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
